RxDoctor Payments DataLook up a doctor →

Neal Bhatia, MD

Dermatology · San Diego, CANPI 1255349288

Payments from drug & device makers

$5,058,469in general payments, 2019–2025

Across 3,917 payments — averaging $1291.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$558K
  • AbbVie$541K
  • Sun Pharmaceutical Industries Inc.$432K
  • Regeneron$268K
  • Sanofi$252K
  • Eli Lilly$238K
  • plus $2.8M from 54 others
$42,797in research payments, 2019–2025

Across 21 payments — averaging $2037.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bausch Health US, LLC$20K
  • Pfizer$9K
  • Mayne Pharma Commercial LLC$6K
  • Eli Lilly$6K
  • Amgen$2K

What the payments were for

  • Consulting fees$630,69925%
  • Speaking & faculty fees$1,555,26063%
  • Travel & lodging$169,7487%
  • Food & beverage$98,9014%
  • Education$31,3801%
  • Gifts$1170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.291$558,488
AbbVie(2 entities)403$541,122
Sun Pharmaceutical Industries Inc.380$432,491
Regeneron123$268,361
Sanofi238$252,226
Eli Lilly15$237,603
Pfizer177$234,240
Aclaris Therapeutics, Inc.39$200,541
Ortho Dermatologics, A Division Of Bausch Health US, LLC259$187,416
Takeda Pharmaceuticals U.S.A., Inc.90$177,266
Almirall LLC121$165,925
Regeneron Healthcare Solutions, Inc.187$158,232
Bristol Myers Squibb7$148,912
LEO Pharma Inc.183$143,990
Amgen45$130,484
Bausch Health US, LLC43$119,756
Boehringer Ingelheim58$113,755
Novartis104$96,183
Mindera Corp13$92,139
Arcutis Biotherapeutics, Inc.136$85,213
Journey Medical Corporation37$79,704
Janssen Research & Development, LLC38$74,225
Incyte Corporation133$73,965
VYNE Pharmaceuticals Inc.57$68,546
Galderma Laboratories, L.p.106$63,780
Biofrontera Inc.65$59,511
Verrica Pharmaceuticals Inc.33$45,631
UCB, Inc.133$45,260
Sanofi US Services Inc.11$40,951
Lilly USA, LLC58$32,266
EPI Health, LLC43$23,211
Boehringer Ingelheim International GmbH7$17,502
LNHC, Inc17$14,223
Dermavant Sciences, Inc.63$12,552
LEO Pharma AS5$9,512
Stemline Therapeutics Inc.8$8,949
Boehringer Ingelheim Pharma GmbH & Co.kg4$6,153
DUSA Pharmaceuticals, Inc.3$6,042
Janssen Scientific Affairs, LLC11$5,822
Zerigo Health, Inc.3$5,656
UCB SA1$4,531
Johnson & Johnson(2 entities)73$3,081
Sensus Healthcare, Inc.3$2,665
Dr.reddy's Laboratories,inc.2$1,696
Organon14$1,539
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$1,400
Astrazeneca UK Limited1$1,000
Sanofi-aventis U.S. LLC26$949
Kowa Pharmaceuticals America, Inc.1$750
Abbott11$718
Promius Pharma LLC3$561
Mayne Pharma Commercial LLC3$334
Dermira, Inc.9$301
Chiesi USA, Inc.4$169
ANI Pharmaceuticals, Inc.2$156
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC2$156
Blueprint Medicines Corporation3$121
Sandoz1$120
Encore Dermatology Inc.1$120
Avita Medical Americas, LLC2$95

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,058,469 in reported general payments places this provider in the 95th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California

Medicare billing

Part B allowed, 2024
$17,014
Medicare patients
53
Services billed
179

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other dermatology in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →